|
DMAC | Diamedica Therapeutics Inc. |
|
|
DMAC | Diamedica Therapeutics Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.16 |
| Leverage | 9.51% |
| Market Cap | $ 322.2m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -31.8m |
| Margin | -3341.28% |
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.